title: [Strategies in castration-resistant prostate cancer].
abstract: The treatment of a castration-resistant prostate cancer can be immediate or delayed according to the circumstances and the time of its occurrence. New therapeutic targets have been determined with basic tumor biology studies. Treatments available or on development are various and range from estrogens to new anti-androgens. Endothelin inhibitors, abiraterone, MDV3100 or RD162 are the most promising examples but they require to enroll patients in therapeutic trials.
authors.affiliation: Service d'Urologie, Hôpital Bicêtre, 78, rue du Général Leclerc, 94275 Le Kremlin-Bicêtre Cedex, France. thomas.bessede@gmail.com
authors.forename: T
authors.initials: T
authors.lastname: Bessede
authors.forename: P
authors.initials: P
authors.lastname: Beuzeboc
authors.forename: F
authors.initials: F
authors.lastname: Bladou
authors.forename: K
authors.initials: K
authors.lastname: Fizazi
authors.forename: P
authors.initials: P
authors.lastname: Mongiat-Artus
authors.forename: A
authors.initials: A
authors.lastname: Villers
mesh_terms: D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*